Drug intelligence / Profile preview

VRB103

Development stage: Phase 1
Lead developer: Verdiva Bio
Modality: Peptides, Small Molecules
Administration: Oral

Overview

VRB103 is an investigational synthetic peptide drug being developed as a once-weekly oral dual-acting amylin and calcitonin receptor agonist (DACRA) for the treatment of obesity. It acts as an agonist at the amylin receptor (AMYR), targeting mechanisms involved in appetite regulation and energy balance. The drug is designed to leverage gut-brain biology to provide enhanced efficacy and improved tolerability compared to existing therapies. As of early 2025, it remains in preclinical development with no reported clinical trial results in humans[1][2][5]. Verdiva Bio is advancing this program as part of its portfolio focused on next-generation anti-obesity therapies[3].

Other names: Oral Amylin Receptor Agonist (Sciwind)

Targets

AMY receptor (Calcitonin receptor (with ramps))CALCR (Calcitonin receptor)

Beyond the preview

Go deeper on VRB103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRB103.

Explore the full profile